Evidence map›Paper›PMID 23343395›Full record

Trial reportAIDS research and human retroviruses2013

Issues in women's participation in a phase III community HIV vaccine trial in Thailand.

Jaranit Kaewkungwal, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Chirasak Khamboonruang, Prayura Kunasol, Pravan Suntharasamai, Swangjai Pungpak, Sirivan Vanijanonta, Valai Bussaratid and 9 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in AIDS research and human retroviruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Hidden in plain sight: sex and gender in global pandemics.Current opinion in HIV and AIDS · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Jaranit Kaewkungwal1 Center of Excellence for Biomedical and Public Health Informatics, Faculty of Tropical Medicine, Mahidol University , Bangkok, Thailand .
Punnee Pitisuttithum
Supachai Rerks-Ngarm
Sorachai Nitayaphan
Chirasak Khamboonruang
Prayura Kunasol
Pravan Suntharasamai
Swangjai Pungpak
Sirivan Vanijanonta
Valai Bussaratid
Wirach Maek-A-Nantawat
Jittima Dhitavat
Prasert Thongcharoen
Rungrawee Pawarana
Yupa Sabmee
Mike W Benenson
Patricia Morgan
Robert J O'Connell
Jerome Kim
Mahidol University · THArmed Forces Research Institute of Medical Science · THMinistry of Public Health · THMahidol Oxford Tropical Medicine Research Unit · THSiriraj Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess qualities and outcomes of women participating in a large, community-based HIV vaccine trial, the present study was conducted among female participants of the RV 144 prime-boost trial in Thailand from 2003 to 2009. Qualities of participation refer to complete vaccination, retention, and status change. Outcomes of participation refer to incident rate, adverse event, and participation impact event. A total of 6,334 (38.6%) women participated in the trial, of whom about 50% were classified as low risk and 11% as high risk. About 85% of participants completed four vaccinations and 76% were included in the per-protocol analysis of the on-time vaccination schedule. More women (88%) completed 42 months follow-up compared with men (85%). Women aged 21 and above had more adverse events compared to younger age groups. More women (5%) compared with men (3%) reported participation impact events (PIEs). High-risk women had more PIEs and a higher infection rate compared to the low-risk group. Complete vaccination and retention on last follow-up were more common in married women aged above 21, and being a housewife. Female volunteers showed the same qualities and outcomes of participation as males in the HIV vaccine trial. There was no statistically significant difference in vaccine efficacy between men and women, especially among the high-risk and married women. The study highlighted the important behavioral, social, and cultural issues that could be considered for future HIV vaccine trial designs.

Indexed as

AdultAIDS VaccinesFemaleHIV InfectionsHumansMaleMedication AdherenceSex FactorsSocial BehaviorSocioeconomic FactorsThailandYoung AdultAIDS Vaccines

Identifiers

PMID23343395
PMCPMC3809940
OpenAlexW2037488299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.